Evra Health

Cover Block

Name	Evra Health
Tagline	An AI health companion that turns your labs, wearables, and health history into simple daily actions. [evrahealth.com, retrieved 2024]
Headquarters	Washington, US [evrahealth.com, retrieved 2024]
Founded	2024 [evrahealth.com, retrieved 2024]
Stage	Pre-Seed
Business Model	Direct-to-Consumer (DTC)
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Global / Remote-First
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Pre-Seed (total disclosed ~$1,000,000) [Perplexity Sonar Pro Brief, retrieved 2026]

Links

• Website: https://evrahealth.com/
• LinkedIn: https://www.linkedin.com/company/evra-health

Data Accuracy: GREEN -- Confirmed by direct access to the company website and its LinkedIn profile.

Executive Summary

Evra Health is an early-stage AI-native health companion that aims to translate fragmented personal health data into a structured, daily regimen for chronic disease prevention. Founded in 2024 by physician and epidemiologist Dr. Amitha Kalaichandran, the company launched its waitlist in April, positioning itself as a direct-to-consumer platform that synthesizes lab results, wearable data, and health history into personalized action steps [Evra Health, retrieved 2024]. The founding wedge is a combination of clinical rigor and lifestyle-focused guidance, seeking to fill the gap between episodic medical visits with continuous, AI-driven support for conditions ranging from diabetes and hypertension to Long COVID and general wellness [Perplexity Sonar Pro Brief, retrieved 2024].

Dr. Kalaichandran brings a relevant, multi-disciplinary background to the venture, including medical training, a master's in health science, board certification in public health, and fellowship training in integrative medicine [Dr. Amitha, retrieved 2026]. The company's initial capitalization is a reported $1,000,000 pre-seed round [Perplexity Sonar Pro Brief, retrieved 2026].

Data Accuracy: YELLOW -- Core product description and founder background are well-sourced; funding details are from a single aggregated report.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Direct-to-Consumer (DTC)
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Global / Remote-First
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Pre-Seed (total disclosed ~$1,000,000)

How the Company Got Here

Evra Health was founded in 2024, launching its waitlist in April of that year [Dr. Amitha, 2026]. The company is headquartered in Washington, US, and operates a remote-first model, targeting a global consumer audience [Perplexity Sonar Pro Brief, 2024]. The entity is structured as a direct-to-consumer (DTC) business.

The founding narrative centers on Dr. Amitha Kalaichandran, a physician, epidemiologist, and author [About - Evra Health, 2026]. A $1,000,000 pre-seed round was reported in 2024 [Perplexity Sonar Pro Brief, retrieved 2026].

Data Accuracy: YELLOW - Company details and founder background are confirmed via primary sources; the $1,000,000 pre-seed figure is reported from a single source.

Product and Technology

Evra Health presents as an AI-native platform designed to function as a continuous health companion, translating disparate personal health data into a structured plan for chronic disease management. The core proposition is to ingest a user's lab results, wearable device streams, and self-reported health history, then output what the company calls "simple daily actions" grounded in integrative and lifestyle medicine [Perplexity Sonar Pro Brief, retrieved 2024].

The platform's intended scope is broad, targeting over a dozen specific chronic conditions including hypertension, diabetes, obesity, autoimmune disorders, and post-viral syndromes [Evra Health, retrieved 2024]. Its go-to-market is direct-to-consumer, with a waitlist launched in April 2026 [Evra Health Launches in April for Personalized Preventive..., 2026].

Data Accuracy: YELLOW -- Product claims are consistent across the company's owned channels and founder communications, but technical implementation details are not publicly available.

Where the Demand Sits

The market for AI-driven chronic disease management is coalescing around a clear need, as traditional healthcare systems struggle to provide continuous, personalized support for the growing burden of long-term conditions.

The global digital health market was valued at approximately $211 billion in 2022 and is projected to reach $809 billion by 2030 [Grand View Research, 2023]. Consumer adoption of wearable devices has created a new stream of real-world health data, estimated at over 1 billion connected devices globally [IDC, 2023]. Chronic disease is estimated to account for over 85% of U.S. healthcare spending [CDC, 2022].

Metric	Value
Digital Health Market 2022	$211B
Digital Health Market 2030 (projected)	$809B

Data Accuracy: YELLOW -- Market sizing from a single third-party report; demand drivers and regulatory context are widely reported but not specifically tied to the company's model.

Competitive Landscape

Evra Health enters a market defined by a crowded field of digital health applications, positioning itself at a specific intersection of AI-driven personalization, integrative medicine, and direct-to-consumer chronic disease management.

Competitors include broad wellness platforms like Fitbit and Apple Health, condition-specific digital therapeutics like Omada Health and Livongo, and AI-powered health assistants like Ada Health [Apple, 2024] [Teladoc, 2024] [Ada Health, 2024]. Evra's defensible edge rests on its founder's clinical and public health expertise [Dr. Amitha, 2026].

Data Accuracy: YELLOW -- Competitive analysis is based on public positioning of named companies; direct competitive intelligence on Evra's market share is not available.

Opportunity

The prize for Evra Health is a redefinition of the patient journey for chronic disease management, moving from reactive, episodic care to a continuous, AI-guided partnership [Evra Health, retrieved 2024].

Scenario	What happens	Catalyst	Why it's plausible
Direct-to-Consumer Premium Subscription	Evra scales as a global, direct-to-patient subscription service.	A successful, data-driven pilot in the U.S. and India.	The DTC model bypasses slow enterprise sales cycles.
B2B2C Payer/Employer Partnership	Evra is white-labeled or integrated as a value-based care tool.	Securing a pilot partnership with a regional health plan.	The company's website includes a page targeting employers and health plans.

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated vision and target markets. Growth scenarios are plausible extrapolations but lack external validation.

Sources

1. [evrahealth.com, retrieved 2024] Evra Health | https://evrahealth.com/
2. [Dr. Amitha, retrieved 2026] Dr. Amitha | https://dramitha.com/
3. [About - Evra Health, retrieved 2026] About - Evra Health | https://evrahealth.com/about/
4. [Evra Health Launches in April for Personalized Preventive..., 2026] Evra Health Launches in April for Personalized Preventive Health | https://evrahealth.com/
5. [The New York Times, 2020] Opinion | How Can We Bear This Much Loss? | https://www.nytimes.com/2020/09/23/opinion/grief-covid-book-of-job.html
6. [Grand View Research, 2023] Digital Health Market Size Report, 2023-2030 | https://www.grandviewresearch.com/industry-analysis/digital-health-market
7. [IDC, 2023] Worldwide Wearables Market Forecast, 2023 | https://www.idc.com/
8. [CDC, 2022] Chronic Diseases in America | https://www.cdc.gov/chronicdisease/index.htm
9. [Apple, 2024] Apple Health | https://www.apple.com/ios/health/
10. [Teladoc, 2024] Teladoc Health | https://www.teladochealth.com/
11. [Ada Health, 2024] Ada Health | https://ada.com/
12. [Business Wire, 2023] Omada Health Announces New Clinical Data | https://www.businesswire.com/news/home/20230523005321/en/